This retrospective cohort study developed and validated a risk prediction model for prostate cancer in 290 patients clinically diagnosed with prostate lesions between March 2023 and October 2024. The model integrated multimodal quantitative MRI parameters (T2WI, T1WI, DWI, synthetic relaxometry, IDEAL-IQ, APT) with clinical data. The comparator was a non-prostate cancer group.
Analysis revealed significant differences in all quantitative MRI parameters and clinical data (except for age) between the prostate cancer group (140 patients) and the non-prostate cancer group (150 patients). The model demonstrated good performance in discrimination, stability, consistency, and clinical applicability, with a reported substantial net benefit. Inter-rater consistency for MRI parameters between two radiologists was good, with intraclass correlation coefficients (ICCs) exceeding 0.75.
Safety and tolerability data were not reported. Key limitations were not explicitly stated in the provided data. The authors suggest the model offers potential advantages in data objectivity, reproducibility, non-invasiveness, cost-effectiveness, and operational simplicity compared to existing diagnostic approaches. However, as a retrospective, single-center model development study, its findings require external validation in prospective, multi-center settings to assess real-world clinical utility and generalizability before it can inform practice.
View Original Abstract ↓
ObjectivesTo develop and validate a predictive model for prostate cancer (PCa)by integrating quantitative MRI and clinical data.MethodsA retrospective study was conducted on 290 patients clinically diagnosed with prostate lesions between March 2023 and October 2024. All patients underwent multimodal quantitative MRI preoperatively, including T2-weighted imaging (T2WI), T1-weighted imaging (T1WI), diffusion-weighted imaging (DWI, b=0, 500 mm2/s), synthetic relaxometry (MAGiC), iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantitation (IDEAL-IQ), and amide proton transfer (APT) sequences. Based on pathological results, patients were stratified into PCa group (n=140) and Non-PCa group (n=150). All quantitative parameters derived from multimodal MRI were measured independently by a dedicated team of radiologists, and their reproducibility was assessed through intra−class correlation coefficients (ICCs). Differences in all MRI quantitative parameters and clinical data between the groups were compared. All patients were randomly divided into a training group (203 cases) and a validation group (87 cases) at a ratio of 7:3. The Least Absolute Shrinkage and Selection Operator (LASSO) and Logistic regression were used to screen independent predictive parameters for PCa, constructing a predictive model, internal validation and bootstrap validation were performed on the model. The model was evaluated using receiver operating characteristic curves (ROC), goodness-of-fit tests (Hosmer-Lemeshow statistic), calibration curves, and decision curve analysis (DCA), and presented in the form of nomograms.Results1) Two radiologists showed good consistency (ICCs > 0.75). 2) There were significant differences between the PCa and non-PCa groups for all variables except age(P 0.05), and a substantial net benefit on decision curve analysis.ConclusionThe prediction model based on quantitative MRI and clinical parameters has good performance in discrimination, stability, consistency and clinical applicability. Compared to existing diagnostic models, it offers distinct advantages in data objectivity, reproducibility, non-invasiveness, cost-effectiveness, and operational simplicity.